I dont think you understand the dynamics of the stock and company finances.
They are running the company by selling stock. Near zero sales and revenue
they do not have FDA approval except for their prescription only version for eye surgery recovery.
$300,000 is a TON of money - 150 MILLION shares at current price.
dilution for that would be stupid, one of their best decisions was to stop being SEC reporting to save money.
people here critize sale strips to conferences where they meet with many distributors or partners of their lead distributors for Europe. that is a few thousand (and may not be expensed yet).
All that matters at the moment is only spend money involved in selling in Canada and UK direct (advertising) and suplying more product to distributors, plus keep paying phone bill so the fax from the FDA will get through,
News 
Market Data 
Discover 
